Rochester, NY - Researchers are calling for beta-blocker treatment for patients with intermittent claudication, arguing that it is "old school" to avoid them in this high-risk group [1]. The new study ...

Although pentoxifylline and cilostazol may provide symptomatic relief, the management of IC must address the underlying problem of PVD. Resolution of risk factors, such as smoking, diabetes, ...

Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced it has completed the planned enrollment of 150 patients in a global Phase II trial of its ...

Motivating patients with peripheral artery disease (PAD) and intermittent claudication to start walking at home improved their exercise capacity, the MOSAIC trial showed. Six-minute walk distance ...

Exercise has been used in the treatment of many medical conditions, including heart and lung diseases. But it can also play an important role in treating peripheral artery disease. Our latest review ...

Drug-coated stents and balloons were not associated with reduced risk of amputation or improved quality of life compared with uncoated devices in two trials in peripheral artery disease (PAD), ...

* Pluristem's IC trial is evaluating safety and efficacy of PLX-PAD cells as compared to placebo Source text for Eikon: Further company coverage: ...